STTK

Shattuck

--

--(--)

Market Open: --

--

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

Revenue Beats Expectation

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

--

Prev.Close

--

%Range

--

Turnover

--

Avg Vol(4W)

--

Market Cap

--

Div.Yield

--

P/E(TTM)

--

EPS(TTM)

--

Beta

--

Free Float

--

Shares Outstanding

--

%Turnover

--

P/E(DYN)

--

P/B

--

BVPS

--

High

--

Low

--

52 Week High

--

52 Week Low

--

About STTK

Shattuck Labs, Inc.

A clinical-stage biotech company pioneering bi-functional fusion proteins as a new class of biologic medicine for cancer and autoimmune disease

Industry

Biological Technology

Established Date

05/09/2016

Listing Date

10/09/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

44

Fiscal Year Ends

12-31

Website

www.shattucklabs.com

Security Type

Common stock

Office address

500 W. 5th Street, Suite 1200, Austin, TX 78701

Business

--

Introduction

Shattuck Labs, Inc., was incorporated in Delaware on May 9, 2016. The company is an innovative clinical-stage biotechnology company dedicated to the development of double-sided fusion proteins as an entirely new biomedical product.

Company Financials

EPS

STTK has released its 2024 Q4 earnings. EPS was reported at -0.37, versus the expected -0.32, missing expectations. The chart below visualizes how STTK has performed over recent quarters, highlighting trends in earnings surprises.